Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00519389 · ClinicalTrials.gov registry record · Phase 1

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

A Phase 1 study, sponsored by Novavax.

Completed
Registry status
Phase 1
Development phase
230
Enrollment target

NCT00519389: Completed Phase 1 study, sponsored by Novavax.

NCT00519389 is a Phase 1 study that has completed, run by Novavax. The registered enrollment target is 230 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (283% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00519389, a Phase 1 study, has completed, sponsored by Novavax.

COMPLETED
Registry status
Phase 1
Development phase
230 participants
Enrollment target

Study Summary

This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL H5N1 VLP Vaccine

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2007-07
Est. Completion 2008-11
Phase Phase 1
Novavax

31 total trials

What the finished NCT00519389 record still lists

NCT00519389 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (283% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00519389 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00519389 about?

NCT00519389 is a clinical study titled "Safety, Reactogenicity and Immunogenicity of an H5N1 VLP". This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.

What is the current status of trial NCT00519389?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2007-07. Estimated completion is 2008-11.

What interventions are being tested in trial NCT00519389?

The interventions under investigation include: Placebo (BIOLOGICAL), H5N1 VLP Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00519389?

This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00519389's enrollment target sits among peer trials

230 219th of 2000 higher than 1,780 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00519389, the US trial registry maintained by the National Library of Medicine. NCT00519389 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.